1. Epstein J. Pathology of prostatic neoplasia.

In: Wein A, Kovoussi L, Novick A, et

al. (eds) Campbell-Walsh Urology. Philadelphia, 2007, pp. 2874–82.
2. Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008:
GLOBOCAN 2008. Int J Cancer 2010; 127: 2893–2917.
3. Mottet N, Schalken J, Heidenreich A, et al. Highlights on Prostate Cancer from
Urological and Oncological Congresses in 2007. Eur Urol Suppl 2008; 7: 460–73.
4. Murai M, Cheng C, Khauli R, et al. Prostate cancer: 6th international consultation
on new developments in prostate cancer and prostate diseases. 2006. Epub ahead of
print 2006. DOI: 10.1016/j.juro.2007.01.121.
5. Klein E, Platz E, Thompson I. Epidemiology, Etiology, and Prevention of Prostate
Cancer. In: Wein A, Kovoussi L, Novick A, et al. (eds) Campbell-Walsh Urology.
Philadelphia, 2007, pp. 2854–73.
6. Indonesian Society of Urologic Oncology (ISUO). ISUO Meeting 2011. 2011.
7. Kelompok Kerja Kanker Urologi RS. Cipto Mangunkusumo - RS. Kanker
Dharmais. Panduan pengelolaan kanker prostat. Interna Publishing, 2009.
8. Umbas R, Muchtar C, Hamid R. Terapi radikal pada penderita kanker prostat:
tindak lanjut jangka panjang dan faktor prediksi survival. Indones J Cancer 2010;
4: 55–60.
9. Safriadi F. Karakteristik dan pola penanganan Kanker prostat di RS. Hasan
Sadikin Bandung. Indones J Cancer.
10. Mahadi E, Widjanarko S. Penanganan karsinoma prostat di RSUD dr. Moewardi
Surakarta selama Januari 2000-Desember 2006. J Urol Indones 2009; 16: 25–28.
11. Gann PH. Risk factors for prostate cancer. Rev Urol 2002; 4 Suppl 5: S3–S10.
12. Wolk A. Diet, lifestyle and risk of prostate cancer. Acta Oncol
2005; 44: 277–81.
13. Kolonel L. Fat, meat, and prostate cancer. Epidemiol Rev 2001; 23: 72–81.
-67-
14. Giovannucci E, Rimm E, Wolk A. Calcium and fructose intake in relation to risk
of prostate cancer. Cancer Res 1998; 58: 442–7.
15. Ostrander EA, Udler MS. The role of the BRCA2 gene in susceptibility to prostate
cancer revisited. Cancer Epidemiol Biomarkers Prev 2008; 17: 1843–1848.
16. Cavanagh H, Rogers KMA. The role of BRCA1 and BRCA2 mutations in prostate,
pancreatic and stomach cancers. Hered Cancer Clin Pract 2015; 13: 16.
17. Plaskon LA, Penson DF, Vaughan TL, et al. Cigarette Smoking and Risk of
Prostate Cancer in Middle-Aged Men 1. 2003; 12: 604–609.
18. Huncharek M, Sue Haddock K, Reid R, et al. Smoking as a risk factor for
prostate cancer: A meta-analysis of 24 prospective cohort studies. Am J Public
Health 2010; 100: 693–701.
19. Richie J, Catalona W, Ahmann F, et al. Effect of patient age on early detection of
prostate cancer with serum prostate-spesific antigen and digital rectal examination.
Urology 1993; 42: 356–74.
20. Carvalhal G, Smith D, Mager D, et al. Digital rectal examination for detecting
prostate cancer at prostate specific antigen levels of 4ng/ml or less. J Urol 1999;
161: 835–9.
21. Stamey T, Yang N, Hay A, et al. Prostate-specific antigen as a serum marker for
adenocarcinoma of the prostate. N Engl J Med 1987; 317: 909–16.
22. Catalona W, Richie J, Ahmann F, et al. Comparison of digital rectal examination
and serum prostate specific antigen in the early detection of prostate cancer: results
of a multicenter clinical trial of 6,630 men. J Urol 1994; 151: 1283–90.
23. Lee F, Torp-Pedersen S, Siders D, et al. Transrectal ultrasound in the diagnosis
and staging of prostate cancer. Radiology 1989; 170: 609–15.
24. Takenaka A, Hara R, Ishimura T. A prospective randomized comparison of
diagnostic efficiency between transperineal and transrectal 12-core prostate biopsy.
Prostate Cancer Prostatic Dis; 11: 134–8.
25. Hara R, Jo Y, Fujii T, et al. Optimal approach for prostate cancer detection as
initial biopsy: prospective randomized study comparing transperineal versus
transrectal systematic 12-core
-68-
biopsy. Urology 2008; 71: 191–5.
26. Eichler K, Hempel S, Wilby J, et al. Diagnostic value of systematic biopsy
methods in the investigation of prostate cancer: a systematic review. J Urol 2006;
175: 1605–12.
27. Donovan J, Handy F, Neal D, et al. Prostate Testing for Cancer and Treatment
(ProtecT) feasibility study. Heal Technol Assess 2003; 7: 1–88.
28. Aziz A, Hakim L, Soebadi D. Comparison of sextant and 10-core biopsy for the
detection of prostate cancer. J Urol Indones.
29. Monn MF, Flack CK, Koch MO. Prostate Cancer. ProstateCance2016; 551–562.
30. Shepherd D, Keetch D, Humprey P, et al. Repeat biopsy strategy in men with
isolated prostatic intraepithelial neoplasia on prostate needle biopsy. J Urol; 156.
31. Merrimen J, Jones G, Walker D, et al. Multifocal high grade prostatic
intraepithelial neoplasia is a significant risk factor for prostatic adenocarcinoma. J
Urol 2009; 182: 485–90.
32. Stewart C, Leibovich B, Weaver A, et al. Prostate cancer diagnosis using a
saturation needle biopsy technique after previous negative sextant biopsies. J Urol
2001; 166: 86–92.
33. Zigeuner R, Schips L, Lipsky R. Detection of prostate cancer by TURP or open
surgery in patients with previously negative transrectal prostate biopsies. Urology;
62: 883–7.
34. Aron M, Rajeev T, Gupta N. Antibiotic prophylaxis for transrectal needle biopsy
of the prostate: a randomized controlled study. BJU Int; 85: 682–5.
35. Sipan G, Umbas R, Rahardjo D. Profilaksis ciprofloxacin oral dosis 1 hari versus
3 hari pada biopsi prostat transrektal dengan penuntun ultrasonografi. JURI 2004;
11: 25–30.
36. Wendy R, Safriadi R. Periprostatic block and intraprostatic infiltration on TRUS-
P guiden biopsy: Effectivity and Complication. Indones J Cancer.
37. Haswir H, Umbas R. Comparison of Efficacy between oral morphine sulphate
and diclofenac suppository for analgesia during Transrecrtal Ultrasound-guided
Prostate biopsy. Indones J Intern Med 2008; 40: 124–127.
38. Alvarino, Umbas R. Penggunaan anestesi lokal periprostat
-69-
sebelum biopsi prostat transrektal. Maj Kedokt Indon 2005; 55:397–401.
39. Azis A, Djatisoesanto W, Soebadi D, et al. The difference of pain perception
between ketoprofen suppository and 1% periprostatic licocain injection in
transrectal ultrasonography guided prostate biopsy. J Urol Indones.
40. Ariffin A, Safriadi F. Comparison efficacy Periprostatic Nerve Block (PNB) vs. PNB
Combined with 2% Lidocaine Gel for Prostate biopsy. J Urol Indones.
41. Epstein J. An update of the Gleason grading system. J Urol 2010; 183: 433–440.
42. Edge S, Byrd D, Compton C, et al. (eds). AJCC cancer staging manual. 7th ed.
Springer, 2010.
43. Spigelman S, McNeal J, Freiha F. Rectal examination in volume determination of
carcinoma of the prostate clinical and anatomical correlations. J Urol 1986; 136:
1228–30.
44. Lee N, Newhouse J, Olsson C, et al. Which patients with newly diagnosed
prostate cancer need a computed tomography scan of the abdomen and pelvis? An
analysis based on 588 patients. Urology 1999; 54: 490–4.
45. Jager G, Severens J, Thornbury J. Prostate cancer staging: should MR imaging
be used? A decision analytic approach. Radiology 2000; 215: 445–51.
46. Partin A, Mangold L, Lamm D. Contemporary update of the prostate cancer
staging nomograms (Partin tables) for the new millennium. Urology 2001; 58: 843–8.
47. Heidenreich A, Varga Z, Von Knobloch R. Extended pelvic lymphadenectomy in
patients undergoing radical prostatectomy: high incidence of lymph node
metastasis. J Urol 2002; 167: 1681–6.
48. McGregor B, Tulloch A, Quinlan M. The role of bone scanning in the assessment
of prostatic carcinoma. Br J Urol 1978; 50: 178– 81.
49. O’Donoghue E, Constable A, Sherwood T. Bone scanning and plasma
phosphatases in carcinoma of the prostate. Br J Urol 1978; 50: 172–7.
50. Wolff J, Zimny M, Borchers H. Is prostate-specific antigen a
-70-
reliable marker of bone metastasis in patients with newly diagnosed cancer of the
prostate? Eur Urol 1998; 33: 376–81.
51. Bruwer G, Heyns C, Allen F. Influence of local tumour stage and grade on
reliability of serum prostate-specific antigen in predicting skeletal metastasis in
patients with adenocarcinoma of the prostate. Eur Urol 1999; 35: 223–7.
52. Huggins C, Hodges C. Studies on prostatic cancer I. The effect of castration, of
estrogen and of androgen injection on serum phosphatase in metastatic carcinoma
of the prostate. J Urol 2002; 167: 948–51.
53. Seidenfeld J, Samson DJ, Aronson N, et al. Relative effectiveness and cost-
effectiveness of methods of androgen suppression in the treatment of advanced
prostate cancer. Evid Rep Technol Assess (Summ) 1999; i–x, 1-246, I1-36, passim.
54. Prostate Cancer Trialists’ Collaborative Group. Maximum androgen blockade in
advanced prostate cancer: an overview of the randomised trials. Prostate Cancer
Trialists’ Collaborative Group. Lancet (London, England) 2000; 355: 1491–8.
55. Schmitt B, Bennett C, Seidenfeld J. Maximal androgen blockade for advanced
prostate cancer. Cochrane Database Syst Rev; 2.
56. Schmitt B, Wilt T, Schellhammer P. Combined androgen blockade with non-
steroidal antiandrogens for advanced prostate cancer: a systematic review. Urology
2001; 57: 727–32.
57. Samson D, Seidenfeld J, Schmitt B. Systematic review and meta- analysis of
monotherapy compared with combined androgen blockade for patients with
advanced prostate carcinoma. Cancer 2002; 95: 361–76.
58. Bruchovsky N, Rennie P, Coldman A. Effects of androgen withdrawal on the stem
cell composition of the Shionogi carcinoma. Cancer Res 1990; 50: 2275–82.
59. Abrahamsson P. Potential benefits of intermittent androgen suppression therapy
in the treatment of prostate cancer: a systematic review of the literature. Eur Urol
2010; 57: 49–59.
60. Hussain M, Tangen C, Higano C. Southwest Oncology Group Trial 9346 (INT-
0162). Absolute prostate-specific antigen value after androgen deprivation is a
strong independent predictor of survival in new metastatic prostate cancer: data
from Southwest
-71-
Oncology Group Trial 9346 (INT-0162). J Clin Oncol 2006; 24: 3984–90.
61. Lane T, Ansell W, Farrugia D. Long-term outcomes in patients with prostate
cancer managed with intermittent androgen suppression. Urol Int 2004; 73: 117–32.
62. Mottlet N, Goussard M, Loulidi S. Intermittent versus continuous maximal
androgen blockade in metastatic (D2) prostate cancer patients. A randomized trial.
Eur Urol Suppl 2009; 8: 131, abstract 44.
63. Byar D. Proceedings: the Veterans Administration Co-operative Urological
Research Group studies of cancer of the prostate.